Almirall sees highest patent filings and grants during August in Q3 2023
Almirall saw the highest growth of 132% in patent filings in August and 99% in grants in July in Q3 2023. Compared to Q2 2023, Q3 2023 saw an increase in patent filings by 99% and grants by 99%. GlobalData's DataBook provides a comprehensive analysis of Almirall's patent filings and grants. Buy the databook here.Almirall has been focused on protecting inventions in European Patent Office(EPO) with 4 publications in Q3 2023The European Patent Office(EPO) Patent Office dominates the patent filings and grants with nearly 43% filings and 33% grants. The European Patent Office(EPO), United States(US), Australia(AU), and South Korea(KR) patent Office are among the top ten patent offices where Almirall is filings its patents. Among the top granted patent authorities, Almirall has 67% of its grants in Australia(AU), 33% in European Patent Office(EPO), and 0% in United States(US).Johnson & Johnson could be the strongest competitor for AlmirallJohnson & Johnson and F. Hoffmann-La Roche secured the top positions according to recent patent publication data.Patents related to rare diseases and lead Almirall's portfolioAlmirall has the highest number of patents in rare diseases followed by, and . For rare diseases, nearly 100% of patents were filed and 0% of patents were granted in Q3 2023.Atopic dermatitis (atopic eczema) related patents lead Almirall portfolio followed by psoriasis, and ileitisAlmirall has highest number of patents in atopic dermatitis (atopic eczema) followed by psoriasis, ileitis, psoriatic arthritis and chronic obstructive pulmonary disease (copd). For atopic dermatitis (atopic eczema), nearly 5% of patents were filed and 0% of patents were granted in Q3 2023.For comprehensive analysis of Almirall's filings and grants, buy the databook here.
Access and buy GlobalData’s databook on the latest filings and grants activity for Almirall here.
What's Your Reaction?
